Ipratropium/salbutamol detailed information

Ipratropium/salbutamol detailed information

Combination of
Ipratropium	Muscarinic antagonist
Salbutamol	Short-acting β2-adrenergic agonist
[[{{{component3}}}]]	? Class
[[{{{component4}}}]]	? Class
[[{{{component5}}}]]	? Class
Clinical data
Routes of administration	Inhalation
Identifiers
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}

WikiDoc Resources for Ipratropium/salbutamol detailed information
Articles
Most recent articles on Ipratropium/salbutamol detailed information Most cited articles on Ipratropium/salbutamol detailed information Review articles on Ipratropium/salbutamol detailed information Articles on Ipratropium/salbutamol detailed information in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Ipratropium/salbutamol detailed information Images of Ipratropium/salbutamol detailed information Photos of Ipratropium/salbutamol detailed information Podcasts & MP3s on Ipratropium/salbutamol detailed information Videos on Ipratropium/salbutamol detailed information
Evidence Based Medicine
Cochrane Collaboration on Ipratropium/salbutamol detailed information Bandolier on Ipratropium/salbutamol detailed information TRIP on Ipratropium/salbutamol detailed information
Clinical Trials
Ongoing Trials on Ipratropium/salbutamol detailed information at Clinical Trials.gov Trial results on Ipratropium/salbutamol detailed information Clinical Trials on Ipratropium/salbutamol detailed information at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Ipratropium/salbutamol detailed information NICE Guidance on Ipratropium/salbutamol detailed information NHS PRODIGY Guidance FDA on Ipratropium/salbutamol detailed information CDC on Ipratropium/salbutamol detailed information
Books
Books on Ipratropium/salbutamol detailed information
News
Ipratropium/salbutamol detailed information in the news Be alerted to news on Ipratropium/salbutamol detailed information News trends on Ipratropium/salbutamol detailed information
Commentary
Blogs on Ipratropium/salbutamol detailed information
Definitions
Definitions of Ipratropium/salbutamol detailed information
Patient Resources / Community
Patient resources on Ipratropium/salbutamol detailed information Discussion groups on Ipratropium/salbutamol detailed information Patient Handouts on Ipratropium/salbutamol detailed information Directions to Hospitals Treating Ipratropium/salbutamol detailed information Risk calculators and risk factors for Ipratropium/salbutamol detailed information
Healthcare Provider Resources
Symptoms of Ipratropium/salbutamol detailed information Causes & Risk Factors for Ipratropium/salbutamol detailed information Diagnostic studies for Ipratropium/salbutamol detailed information Treatment of Ipratropium/salbutamol detailed information
Continuing Medical Education (CME)
CME Programs on Ipratropium/salbutamol detailed information
International
Ipratropium/salbutamol detailed information en Espanol Ipratropium/salbutamol detailed information en Francais
Business
Ipratropium/salbutamol detailed information in the Marketplace Patents on Ipratropium/salbutamol detailed information
Experimental / Informatics
List of terms related to Ipratropium/salbutamol detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

The combination preparation ipratropium/salbutamol is a formulation containing ipratropium bromide and salbutamol sulfate (albuterol sulfate) used in the management of chronic obstructive pulmonary disease (COPD) and asthma. It is marketed by Boehringer Ingelheim as metered dose inhaler (MDI) and nebuliser preparations under the trade name Combivent.

Template:Asthma and copd rx

Template:WikiDoc Sources